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Familial hypertrophic cardiomyopathy (FHC) is associated
with mild to severe cardiac problems and is the leading
cause of sudden death in young people and athletes.
Although the genetic basis for FHC is well-established,
the molecular mechanisms that ultimately lead to cardiac
dysfunction are not well understood. To obtain important
insights into the molecular mechanism(s) involved in FHC,
hearts from two FHC troponin T models (Ile79Asn [I79N]
and Arg278Cys [R278C]) were investigated using label-
free proteomics and metabolomics. Mutations in troponin
T are the third most common cause of FHC, and the I79N
mutation is associated with a high risk of sudden cardiac
death. Most FHC-causing mutations, including I79N, in-
crease the Ca2 sensitivity of the myofilament; however,
the R278C mutation does not alter Ca2 sensitivity and is
associated with a better prognosis than most FHC muta-
tions. Out of more than 1200 identified proteins, 53 and 76
proteins were differentially expressed in I79N and R278C
hearts, respectively, when compared with wild-type
hearts. Interestingly, more than 400 proteins were differ-
entially expressed when the I79N and R278C hearts were
directly compared. The three major pathways affected in
I79N hearts relative to R278C and wild-type hearts were
the ubiquitin-proteasome system, antioxidant systems,
and energy production pathways. Further investigation of
the proteasome system using Western blotting and activ-
ity assays showed that proteasome dysfunction occurs in
I79N hearts. Metabolomic results corroborate the pro-
teomic data and suggest the glycolytic, citric acid, and
electron transport chain pathways are important path-
ways that are altered in I79N hearts relative to R278C or
wild-type hearts. Our findings suggest that impaired
energy production and protein degradation dysfunction
are important mechanisms in FHCs associated with
poor prognosis and that cardiac hypertrophy is not likely
needed for a switch from fatty acid to glucose
metabolism. Molecular & Cellular Proteomics 15:
10.1074/mcp.M115.057380, 1962–1981, 2016.
Familial hypertrophic cardiomyopathy (FHC)1 is the most
common monogenically inherited heart disease, estimated to
affect one in 500 people (1, 2). It is characterized by thickening
of the left ventricle, contractile dysfunction, heart failure, and
a high incidence of potentially lethal arrhythmias (3). Over a
thousand mutations in more than twenty genes have been
identified that cause FHC, most of which encode proteins of
the sarcomere; however, the pathological mechanisms of this
disease are not well understood (1, 3, 4). Mutations in cardiac
troponin T (TnT), encoded by TNNT2, carry a particularly poor
prognosis for the patient and are associated with a high risk of
sudden cardiac death (SCD) (5–8). Most FHC-causing muta-
tions alter how the sarcomere responds to Ca2 by increasing
the myofilament Ca2 sensitivity, which changes its contract-
ile properties and affects Ca2 handling in the cell (9, 10).
Proposed pathological mechanisms include altered cardiac
contractility, changes in Ca2 handling, and altered energy
homeostasis (1, 11). Current treatments include -adrenergic
receptor blockers, Ca2 channel antagonists, myocardial re-
duction by surgical or septal ablation, and implanted defibril-
lators (2). Currently available pharmacological treatments can
provide relief from symptoms and improve patient quality of
life, but they do not target FHC-specific pathways and have
not been shown to slow disease progression (1). An improved
understanding of the molecular mechanisms of FHC is
needed to develop specific therapies that address the under-
lying causes of the disease (2).
Alterations of proteins and pathways that are comorbid with
heart diseases like dilated cardiomyopathy, congestive heart
failure, and myocardial infarction have been identified by pro-
tein mass spectrometry (12). To gain a better understanding of
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the pathways affected in TnT-related FHC, we utilized a label-
free proteomic approach to investigate how hearts from mice
with two different TnT mutations (Ile79Asn [I79N] and
Arg278Cys [R278C]) are affected at the protein level. These
mice (wild-type (WT), R278C, and I79N) all express human
TnT at 50% of the total TnT with the endogenous mouse
TnT accounting for the other 50% (13, 14). Transgenic mice
expressing human TnT are a useful tool for investigating the
disease, as mice with the R278C or I79N mutation show
similar features to humans; humans with the I79N mutation
are at a high risk of sudden cardiac death, and those with the
R278C mutation show a milder phenotype (7, 15–17). To
determine changes at the metabolite level, a time-of-flight gas
chromatography mass spectrometer system (GC-TOF) was
utilized to determine metabolite levels in the different trans-
genic hearts. A major advantage of this investigation is the
comparison of two different FHC models: hearts containing
the myofilament Ca2-sensitizing I79N mutation that is asso-
ciated with poor prognosis and SCD, and the R278C muta-
tion, which does not alter myofilament Ca2 sensitivity and is
associated with mild, late-onset cardiac effects and no SCD
(7, 15–17).
No proteomic or metabolomic comparisons between mild
and severe models of FHC related to sarcomeric mutations
have been reported. Our data reveal that although metabolic
pathways and stress responses were affected in both R278C
and I79N hearts, a major protein complex affected differently
by the two mutations was the proteasome, a large, 2 MDa
complex that is conserved in eukaryotes and responsible for
degrading the majority of cytosolic, nuclear, and nascent
membrane proteins following their modification with the small
protein ubiquitin (18). Through targeted degradation of pro-
teins that are no longer required by the cell, the proteasome
plays a role in virtually all cellular processes (19), and partic-
ularly in cardiomyocyte proteostasis, as these cells are prone
to protein damage due to continual mechanical and metabolic
stresses (20, 21). The heart has very limited capacity for
self-renewal, meaning that cell death, which may result from
impaired proteasome function, can be highly detrimental to
the health of the organ (20, 22). A growing body of evidence
indicates proteasome dysfunction is an important contributor
to the pathogenesis of many cardiac diseases. In FHC caused
by certain mutations in the thick filament-associated protein
cardiac myosin binding protein-C (MyBP-C), the mutated pro-
tein is preferentially degraded by the proteasome, competi-
tively inhibiting breakdown of other proteasome substrates
(23–26). However, some single residue MyBP-C mutants do
not seem to affect ubiquitin-dependent proteasomal proteol-
ysis, and the proteasome has not been implicated in any other
non-MyBP-C FHC model (23). To investigate the effect of TnT
mutations on proteasomal activity, expression and activity of
the proteasome was measured, revealing increased protea-
some subunit expression in I79N hearts relative to R278C
hearts but decreased constitutive proteasome and immuno-
proteasome activities in I79N mice relative to WT and R278C
hearts. This is the first report of immunoproteasome activity
being measured in heart tissue from any animal. Combined
proteomic, metabolomic, immunological, and biological re-
sults all suggest that pathways associated with energy me-
tabolism, protein degradation, and oxidant defense are major
pathways that are altered. These studies show increased
levels of enzymes associated with energy metabolism in I79N
hearts and suggest I79N hearts favor glucose as a substrate
for energy metabolism whereas R278C hearts favor fatty ac-
ids. Thus our findings suggest altered metabolism and pro-
teasome function are likely important molecular mechanisms
involved in TnT-related FHC.
EXPERIMENTAL PROCEDURES
MATERIALS
Urea, DTT, triethylphosphine, iodoethanol, and ammonium bicar-
bonate (NH4HCO3) were purchased from Sigma-Aldrich (St. Louis,
MO). LC-MS grade 0.1% formic acid in ACN and 0.1% formic acid in
water (H2O) were purchased from Burdick & Jackson (Muskegon, MI).
Modified sequencing grade porcine trypsin was obtained from Princ-
eton Separations (Freehold, NJ).
Experimental Animals—All experiments involving animals were ap-
proved by the University of California, Davis Institutional Animal Care
and Use Committee. Transgenic TnT mouse lines generated using the
background mouse strain BL6SJF1/J were used (13, 14). Transgenic
male mice were bred with B6SJLF1/J female mice purchased from
the Jackson Laboratory (Sacramento, CA). Mice were fed standard
chow and water ad libitum and maintained on a 12 h dark/light cycle.
Male offspring were used in all studies. DNA was isolated from tail
snips taken from mice at the time of weaning or sacrifice for geno-
typing. Transgenic mice were identified by performing a PCR reaction
with primers to the 630-base pair 3-untranslated region from the
human growth hormone transcript that is included in the transgene
insert (forward primer CTC CTG GCC CTG GAA GTT; reverse primer
CTG GCC AAT ATG GTG AAA CC) (13, 14).
Tissue Collection—Three month old transgenic TnT mice were
used in these studies, an age equivalent to young adulthood in
humans. Mice were euthanized with isoflurane (3%), followed by
cervical dislocation, and hearts were immediately exercised and
briefly washed with ice-cold PBS, weighed, and flash frozen. Hearts
prepared using this method has been previously shown to be excel-
lent for subsequent proteomic investigation (27, 28).
Experimental Design and Statistical Rationale—
Label-Free Proteomics—To 20 mg of pulverized aged-matched
heart muscle each from 3 WT, 4 R278C, and 4 I79N mice 300 l of 8
M urea was added. As described by Sengupta et al. (29), a minimum
of triplicate biological samples with a significance level of 0.05, a 30%
standard deviation, and large effect size, is needed to give a power of
0.69. Each tissue was treated by light sonication and mixing for 1 h
followed by centrifugation at 13,000 rpm for 10 min. The protein
concentration was measured by Bradford assay (30). 20 l (100 g)
was removed and 20 l 100 mM ammonium carbonate, pH 10.8 and
1 ng chicken lysozyme (to serve as an internal standard) were added
to the samples. 40 l of reduction/alkylation mixture (97.5% ACN, 2%
iodoethanol and 0.5% triethylphosphine) was added to each sample,
and the samples were incubated in a 37 °C incubator for 1.5 h. The
samples were speed vacuumed to dryness overnight, and the dry
pellets were resuspended in 50 l ammonium bicarbonate. 2.5 g
trypsin in 100 l ammonium bicarbonate was added to each sample,
and they were incubated at 37 °C for 4 h. 2.5 g trypsin in 50 l
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ammonium bicarbonate was then added to each sample, and they
were incubated at 37 °C overnight.
LC-MS/MS—The digested samples were analyzed using a Thermo
Scientific Orbitrap Velos Pro mass spectrometer coupled with a Sur-
veyor autosampler and MS HPLC system (Thermo Fisher Scientific,
Waltham, MA). Each biological sample was run two independent
times. Tryptic peptides (K/R cleavages) were injected onto a C18
reversed phase column (TSKgel ODS-100V, 3 m, 1.0 mm  150
mm) at a flow rate of 50 l/min. The mobile phases A and B were
LC-MS grade H2O with 0.1% formic acid and ACN with 0.1% formic
acid, respectively. The gradient elution profile was as follows: 5% B
for 5 min, 10–35% B for 150 min, 35–80% B for 10 min, 80% B for 10
min, and 5% B for 5 min. The data were collected in the “Data
dependent MS/MS” mode of FT-IT (MS-MS/MS) with the ESI inter-
face using normalized collision energy of 35% (CID). Dynamic exclu-
sion settings were set to repeat count 1, repeat duration 30 s, exclu-
sion duration 120 s, and exclusion mass width 10 ppm (low) and 10
ppm (high).
Peptide/Protein Identification and Quantification—The acquired
data were searched against the UniProt protein sequence database
of MOUSE (released on 03/19/2014) using X!Tandem algorithms in
the Trans-Proteomic Pipeline (TPP, v. 4.6.3) (http://tools.proteome
center.org/software.php). The Uniprot database used contained
102,778 entries including the decoy sequences (51,389 entries with-
out decoys). General parameters were set to: parent monoisotopic
mass error set as 10 ppm, cleavage semi set as yes, missed cleavage
sites set at 2, static modification set as  44.026215 Da on cysteine
and no variable modifications. Although not including modifications
reduced the number of peptides detected it also prevents ambiguous
modification site assignments. A mass tolerance of 0.8 Da for frag-
ment ion was used and only trypsin as a known contaminant was
excluded in the analysis. The threshold score/expectation value for
accepting individual spectra was the default value in the X!Tandem
program. The searched peptides and proteins were validated by
PeptideProphet (31) and ProteinProphet (32) in the TPP. Only proteins
and peptides with protein probability0.9000 and peptide probability
0.8000 were reported. Protein quantification was performed using a
label-free quantification software package, IdentiQuantXLTM (33). Us-
ing this IdentiQuantXLTM method complex biological samples con-
taining identical amounts of spiked protein standard showed a coef-
ficient of variation (CV) of 8.6% across eight injections between two
groups (33). This program individually aligns the retention time of each
peptide and applies multiple filters for exclusion of unqualified pep-
tides to enhance label-free protein quantification. Briefly, the protein
ID, sequence, charge, m/z, scan time, injection, sample, and group
information are extracted and collected for each peptide, and pep-
tides with identical sequence and charge are considered as a single
peptide entry for further analysis (33). After peptide frequency is
calculated, the first filter removes peptides that were not identified in
at least three different biological replicates. Alignment to determine
peptide retention time was carried out using clustering. Peptide in-
tensity extraction was carried out using “Acquisition time (minutes)”
and “Limit the search to only custom m/z values (ignoring auto-
fragmentedm/z’s)” under Custom SIC Options in the program MASIC
(33). The CV for each peptide in each sample was calculated, and
Pearson’s correlation (for 3 variables) and uncentered Pearson’s
correlation (for 2 variables) methods were utilized to determine the
correlation coefficient of peptides that correspond to a unique protein
ID. The average CV of all the peptides in this investigation was 14.9%.
The intensity of each peptide was compared with all other peptides,
and the average was used as the final correlation coefficient value.
The mass spectrometry data used in this manuscript have been
deposited in the MassIVE (MSV000079538) and ProteomeXchange
(PXD003703) databases.
Protein abundance was calculated using Ap  i  1n(IpFp)i.
Where Ap  protein abundance, Ip  peptide intensity, and Fp 
frequency of peptide sharing. When a peptide was shared by different
proteins, the intensity of this peptide (Ip) was divided by the sharing
frequency (Fp), which decreases the impact of shared peptides (33).
The quantification values were averaged over technical replicates,
and the resulting values were then averaged over biological repli-
cates. Comparisons between WT, R278C, and I79N samples were
carried out using one-way ANOVA (supplemental Table S2). A value of
p  0.05 was considered statistically significant. False discovery rate
(FDR) was estimated by a nonparametric concatenated randomized
target-decoy database search (34). For this experiment and the TPP
settings used, protein identification FDR was  2.35%.
Proteolytic Activity Assays—Powdered mouse cardiac tissue was
homogenized in ice cold 1X homogenization buffer (50 mM Tris, 1 mM
EDTA, 150 mM NaCl, 5 mM MgCl2, 0.5 mM DTT, pH 7.5) using 25
strokes with a glass dounce homogenizer. The homogenates were
centrifuged for 30min at 12,000  g at 4 °C, and the supernatants
removed, quantified with a Nanodrop (Thermo Scientific), and nor-
malized to equal protein concentrations. A portion of the samples
normalized to the same concentration were used for SDS-PAGE to
verify that the samples were equal in protein amount. The proteolytic
activities of the different proteasome and calpain proteases were
quantified by measuring the degradation of specific fluorogenic sub-
strates using a kinetic protocol in the presence or absence of a
specific inhibitor. Unless otherwise noted, all reactions were carried in
96-well flat black plates, run for 75 min at 37 °C, and measured using
excitation and emission wavelengths of 390 nm and 460 nm
respectively.
26S Proteasome Activity—Protein sample (25 g) was combined
with 1 homogenization buffer, bortezomib (bort) or an equal volume
of DMSO, and 100 M ATP, and incubated for 20 min at room
temperature. The reaction was initiated by adding the specific sub-
strate at a final concentration of 100 M. Final concentrations of bort
and specific fluorogenic substrates for each proteolytic proteasome
subunit, respectively were: 1 - 100 M bort, Z-Leu-Leu-Glu-MCA
(Peptide Institute, 3179-v), 5 - 10 M bort, Suc-Leu-Leu-Val-Tyr-
AMC (Bachem, Bubendorf, Switzerland, I-1395). These assays have
been previously described (35, 36).
20S Proteasome Activity—25 g protein sample was combined
with 1 Chemicon Buffer (25 mM HEPES, 0.5 mM EDTA, 0.05%
Nonidet P-40, 0.001% SDS, pH 7.5), bort or an equal volume of
DMSO, and water and incubated for 20 min at room temperature. The
reaction was initiated by adding Suc-Leu-Leu-Val-Tyr-AMC at a final
concentration of 100 M to measure 5 activity. The final concentra-
tions of bort and Suc-Leu-Leu-Val-Tyr-AMC were the same as de-
scribed in the 26S proteasome activity section.
Immunoproteasome Activity—Protein sample (10 g), Immunopro-
teasome Buffer (50 mM Tris, 5 mM MgCl2, 20 mM KCl, 1 mM DTT, pH
7.5), and inhibitor or an equal volume of DMSO were combined and
incubated for 20 min at room temperature. The reactions were initi-
ated by the addition of 25 M fluorogenic substrate. The reaction was
run at 37 °C for 60 min, and the fluorescence intensity was measured
every 5 mins (498 excitation wavelength, 520 excitation wavelength).
The 1i inhibitor and substrate, respectively, were: 50 M bortezomib
and (Ac-Pro-Ala-Leu)2-R110 (AAT Bioquest, Sunnyvale, CA, Cat. No.
13467). The 5i inhibitor and substrate, respectively, were: 20 M
ONX-0914 (Abmole Bioscience Inc., Houston, TX, Cat. No. M2071)
and (Ac-Ala-Asn-Trp)2-R110 (AAT Bioquest, Cat. No. 13455). ONX-
0914 is a 5i inhibitor.
Calpain Activity—Protein sample (50 g) was combined with cal-
pain activation buffer (25 mM Tris, 0.5 mM EDTA, 5 mM CaCl2, 75 mM
NaCl, 0.25 mM DTT), 25 M calpain inhibitor IV (Calbiochem San
Diego, CA) or an equal volume of DMSO, and incubated for 20 min at
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room temperature. The reaction was initiated by adding the fluoro-
genic substrate Suc-Leu-Leu-Val-Tyr-MCA at a final concentration of
50 M (36).
Western Blot Analysis—
Preparation of Cytosolic Cardiac Homogenates—4 SDS Sample
Buffer (8% SDS, 40% glycerol, 0.4% bromophenol blue, 5% -mer-
captoethanol, 240 mM Tris, pH 6.8) was added to cytosolic cardiac
homogenates (prepared as described in the proteasome assays sec-
tion), and the homogenates were boiled for 4 mins at 95 °C.
Preparation of Total Cardiac Homogenates—1 ml of 1 Laemmli
sample buffer with freshly added -mercaptoethanol (Bio-Rad, Her-
cules, CA, Cat. # 161–0737) was added to 20 g powdered cardiac
tissue. The tissue was mixed, incubated at room temperature for 5
mins, and boiled for 5 mins at 95 °C. The protein concentrations were
determined using the RC DC Protein Assay (Bio-Rad, Cat. #
500–0119).
Electrophoresis and Western Blotting—Homogenates (30 g) and
5 l Spectra multicolor broad range protein ladder (product #
26634, Thermo Scientific) were separated on 4–20% 18-well TGX
Precast Gels (Cat. # 567–8094 for Stain-Free gels, Cat. # 567–1094
for conventional gels, Bio-Rad) at 150V, 500mA maximum current.
Stain-Free gels were activated for 1 min by UV transillumination.
The proteins were transferred to a nitrocellulose or PVDF mem-
brane (Trans-Blot Turbo Midi Nitrocellulose, #170–4159/PVDF
Transfer Pack, #170–4157, Bio-Rad) using the Trans-Blot Turbo
Transfer System (# 170–4155, Bio-Rad). The membranes were then
probed with the respective antibodies (supplemental Table S1). All
Western blotting procedures were carried out at room temperature
with agitation except when stated otherwise. Unless otherwise noted,
membranes were blocked for one hour in 3% blotting grade nonfat
milk (Cat. # 170–6404, Bio-Rad) in Tris Buffered Saline (50 mM Tris,
150 mM NaCl, pH 7.5) containing 0.05% Tween-20 (TBST) at room
temperature, then incubated in primary antibody diluted in 1% milk/
TBST for two hours at room temperature and washed three times for
5 mins each in TBST. The membranes were incubated in peroxidase-
conjugated rabbit anti-mouse or anti-rabbit IgG secondary antibody
(Sigma-Aldrich, anti-mouse Cat. # A9044, anti-rabbit Cat. # A9169 or
#A0545, Sigma-Aldrich) diluted 1:5000 in 1% milk/TBST. The mem-
branes were then washed three times for 5 mins each in TBST. Blots
were incubated with Clarity Western ECL Substrate (Cat. # 170–5061,
Bio-Rad) and imaged using the ChemiDoc MP (Cat. # 170–8280,
Bio-Rad) with ImageLab Version 5 (Bio-Rad). When conventional gels
were used, the membrane was stained for total protein with Coomas-
sie Blue to serve as a loading control following the Western blotting
procedure.
OxyBlot—Homogenates were transferred from a Stain-Free gel to a
PVDF membrane. The membrane was immersed in 100% methanol
for 15 s, dried for 5 mins, and equilibrated in 20% methanol/TBS for
5 mins. The membrane was then washed in 2N HCl for 5 mins, and
incubated in 10 mM 2,4-Dinitrophenylhydrazine (DNPH) (Sigma-Al-
drich, Cat. # D199303) prepared in 2N HCl for 5 mins. The membrane
was washed three times, 5 mins each in 2N HCl and five times, 5 mins
each in 100% methanol. The membrane was then blocked in 5%
milk/TBST for one hour and incubated in anti-DNP primary antibody
(supplemental Table S1) for 2 h, followed by three 5 min washes in
TBST. The membrane was then incubated in peroxidase-conjugated
anti-rabbit secondary antibody diluted 1:5000 in 5% milk/TBST for
1 h, washed three times in TBST for 5 min per wash, incubated with
Clarity Western ECL Substrate, and imaged as described in the
previous section.
Ubiquitin Blot—Homogenates were transferred from a Stain-Free
gel to a nitrocellulose membrane and washed three times for 2 min
each with water, then incubated in 0.5% glutaraldehyde in PBS for 20
min. The membrane was washed three times for 5 min each with PBS
and blocked in 5%milk/TTBS (0.1% Tween was used for all steps) for
30 min. The membrane was incubated overnight at 4 °C with mouse
anti-ubiquitin primary antibody (supplemental Table S1) in 1% milk/
TBST. The membrane was washed three times, 5 mins each with
TBST, then incubated for one hour in peroxidase-conjugated anti-
mouse secondary antibody diluted 1:5000 in 1% milk/TBST. The
membrane was washed three times, 5 min each with TBST, incubated
with Clarity Western ECL Substrate, and imaged.
Antioxidant Capacity Assay—The antioxidant capacity assay was
used to measure the antioxidant activity of cardiac cytosolic homo-
genates based on the oxidation rate of ABTS (2,2-azino-di-(3-ethyl-
benzthiazoline-6-sulfonic acid) by the ferryl metmyoglobin radical. 10
mg of powdered heart tissue was homogenized using the Qiagen
(Hilden, Germany) TissueLyser LT (30 oscillations/s for 3 mins at 4 °C)
with a metal bead in 100 l cold 1 Antioxidant Assay Buffer (5 mM
potassium phosphate, 0.9% NaCl, 0.1% glucose, pH 7.4). The ho-
mogenates were centrifuged at 12,000  g for 20 min at 4 °C. The
supernatants were removed and diluted to equal protein concentra-
tions. In a clear 96-well plate, 0.19 M myoglobin and 130.18 mM
ABTS were combined with 24 g homogenate or increasing amounts
of Trolox standard (0, 0.05, 0.1, 0.15 mM Trolox final concentration).
84 M hydrogen peroxide was added to start the reaction. The reac-
tion was incubated for 45 min, and the amount of ABTS radical was
quantified by measuring absorbance at 415 nm. Trolox equivalent
units were calculated based on the Trolox standard curve (37).
Metabolomics—
Sample Preparation for GC-MS—Hearts (3 month old WT, R278C,
and I79N) were pulverized in liquid nitrogen with a mortar and pestle
and kept as 20 mg aliquots at80 °C. Degassed extraction solvent (1
ml) was added to 20 mg of powdered heart tissue sample (three
biological and two technical replicates for each transgenic line) and
homogenized for 45 s using a Turex mini homogenizer. The extraction
solvent was composed of ACN, isopropanol and water in proportions
3:3:2. The samples were then centrifuged at 2500 rpm for 5 min and
the supernatant removed and aliquoted into two 500 l aliquots. One
aliquot was evaporated to complete dryness in a Labconco (Kansas
City, MO) Centrivap cold trap concentrator. The dried aliquot was
then resuspended with 500 l 50% degassed ACN, centrifuged for 2
min at 14,000 g, and the supernatant was transferred to a new tube.
The supernatant was evaporated to dryness and the pellet used for
derivatization.
GC-TOF—GC-TOF was carried out by the UC Davis Metabolomics
core facility. Samples were derivatized with methoxyamine and
MSTFA to trimethylsilation. Fatty acid methyl esters internal stand-
ards were added to the sample, and 500 l of sample was injected
into an Agilent 7890A GC- Pegasus HT TOF MS (Santa Clara, CA).
The 7890A GC is equipped with a Gerstel automatic liner exchange
system (Linthicum, MD). Injection volume was 0.5 l with 10 l/s
injection speed on a splitless injector with a purge time of 25 s. After
each injection the 10 l injection syringe was washed three times with
10 l ethyl acetate. Chromatography was carried out using a 30 m
long, 0.25 mm i.d. Rtx-5Sil MS column (0.25 m 95% dimethyl 5%
diphenyl polysiloxane film) with an additional 10 m integrated guard
column (Restek, Bellefonte, PA). Helium (99.9999% purity) with a
built-in purifier (Airgas, Radnor, PA) was set at constant flow of 1
ml/min and the oven temperature held constant at 50 °C for 1 min and
then increased at 20 °C/min to 330 °C and then held constant for 5
min. Mass spectrometry of the metabolites were carried out using a
Leco Pegasus HT time of flight mass spectrometer controlled by Leco
ChromaTOF software V4.50.8.0 (St. Joseph, MI). The transfer line
temperature between the gas chromatograph and mass spectrometer
was 280 °C. Electron impact ionization at 70V was employed with an
ion source temperature of 250 °C. Acquisition rate was 17 spectra/
second with a scan mass range of 85–500 Da.
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The identities of all metabolites were validated through a multi-
tiered matching algorithm with the UC Davis in-house BinBase data-
base system (38, 39) using retention index information in addition to
mass spectral matching, unique ion characteristics, peak purity, and
signal/noise metadata (38). The quantification values were averaged
over two technical replicates, and the resulting values were then
averaged over biological replicates. Comparisons between WT,
R278C and I79N samples were carried out using one-way ANOVA.
Results are presented as mean 	 standard deviation (S.D.), and a
value of p  0.05 was considered statistically significant.
RESULTS
A label-free proteomics approach was used to uncover
changes in R278C and I79N mouse hearts. Proteomic analy-
sis revealed that there were more changes in R278C than
I79N mice relative to WT, indicating that the changes in I79N
mice are likely to be more profound in nature, because the
I79N hearts show a more severe phenotype. Of 1200 pro-
teins identified, a total of 76 proteins were found to be statis-
tically altered (p  0.05 by ANOVA) when WT and R278C
hearts were compared, whereas 53 proteins were altered in
I79N hearts compared with WT hearts (Table I and supple-
mental Tables S2 and S3). Proteome analysis of complex
biological samples remains challenging mainly due to the
expansive range of protein concentrations. Because of the
large protein concentration range all unfractionated as well as
many fractionated samples suffer an intrinsic bias against low
abundance proteins (40). When R278C hearts were compared
with I79N hearts more than 400 proteins were found to be
significantly altered. This is the first report of proteomic and
metabolomic comparisons between mutations associated
with mild (R278C) and severe (I79N) phenotypes in any sar-
comeric gene. An advantage of this investigation is that both
mutations are well characterized and occur in the same gene
(TnT), which reduces the potential for artifacts when interpret-
ing the results. Another advantage of these studies is that the
I79N and R278C mutations are not associated with hypertro-
phy in patients or in the mouse models (7, 13–17). This al-
lowed us to investigate the disease mechanisms independ-
ently of cardiac hypertrophy.
Metabolic Processes—Mass spectrometry results analyzed
using the Panther program (http://pantherdb.org/) showed
that when comparing WT and R278C or I79N, proteins asso-
ciated with metabolic processes (GO:0008152) were the most
common process altered when differentially expressed pro-
teins were grouped by biological process (Fig. 1). However,
the relative proportion of proteins altered that were part of
metabolic processes were larger for I79N (35.3%) than for
R278C (29.3%). This is consistent with the largest proportion
of proteins altered when comparing R278C with I79N (26.4%)
also being involved in metabolic processes. The next two
biological processes with the most proteins altered when
comparing WT and R278C or I79N were cellular processes
(GO:0009987) and cellular component organization or biogen-
esis (GO:0071840) (Fig. 1). One biological process that ap-
pears to be affected to a lesser degree in R278C versus WT
hearts than I79N versus WT hearts is the apoptosis process
(GO:0006915), which accounted for 2.1% of the altered pro-
teins in I79N versus WT, and only 0.6% of altered proteins in
R278C versus WT. When comparing protein changes based
on molecular function, the greatest proportion of altered pro-
teins were associated with catalytic activity (GO:0003824) for
all comparisons (WT versus R278C or I79N and R278C versus
I79N) (supplemental Fig. S1).
Proteasome Dysfunction—One large protein complex asso-
ciated with metabolic function is the proteasome. The protea-
FIG. 1. Summary of results for the proteomic analysis of wild-type, R278C, and I79N mouse hearts. Biological processes associated
with the differentially expressed proteins are shown as identified using the gene ontology (GO) biological processes classification. Most proteins
are associated with multiple biological functions; they are grouped according to the biological function they are most often associated with.
Proteomic Signatures of Two FHC Animal Models
1966 Molecular & Cellular Proteomics 15.6
TA
B
LE
I
P
ro
te
in
s
w
hi
ch
ar
e
d
iff
er
en
tia
lly
ex
p
re
ss
ed
in
he
ar
ts
fr
om
3
m
on
th
ol
d
w
ild
-t
yp
e,
R
27
8C
an
d
I7
9N
m
ic
e,
gr
ou
p
ed
ac
co
rd
in
g
to
ge
ne
on
to
lo
gy
(G
O
)b
io
lo
gi
ca
lp
ro
ce
ss
.D
et
ai
ls
of
p
ro
te
in
ex
p
re
ss
io
n
ar
e
sh
ow
n
in
su
p
p
le
m
en
ta
lT
ab
le
S
2.
A
b
b
re
vi
at
io
ns
:
m
ito
,
m
ito
ch
on
d
ria
l
I7
9N
ve
rs
us
W
T
R
27
8C
ve
rs
us
W
T
P
ro
te
in
ID
G
en
e
N
am
e
P
ro
te
in
N
am
e
P
ro
te
in
ID
G
en
e
N
am
e
P
ro
te
in
N
am
e
M
et
ab
ol
ic
P
ro
ce
ss
M
et
ab
ol
ic
P
ro
ce
ss
H
7B
X
88
C
ra
t
C
ar
ni
tin
e
O
-a
ce
ty
ltr
an
sf
er
as
e
1
Q
8R
0F
8
Fa
hd
1
A
cy
lp
yr
uv
as
e
FA
H
D
1,
m
ito
.
1
Q
04
44
7
C
kb
C
re
at
in
e
ki
na
se
B
-t
yp
e
1
O
35
14
3
A
tp
if1
A
TP
as
e
in
hi
b
ito
r,
m
ito
.
2
Q
9D
C
W
5
C
ox
6a
1
C
yt
oc
hr
om
e
c
ox
id
as
e
su
b
un
it
6A
,
m
ito
.
1
Q
8V
C
T4
C
es
1d
C
ar
b
ox
yl
es
te
ra
se
1D
1
Q
9D
C
W
5
C
ox
6a
2
C
yt
oc
hr
om
e
c
ox
id
as
e
su
b
un
it
6A
2,
m
ito
.
1
Q
99
LC
5
E
tf
a
E
le
ct
ro
n
tr
an
sf
er
fla
vo
p
ro
te
in
su
b
un
it
al
p
ha
,
m
ito
.
1
P
10
51
8
A
la
d
D
el
ta
-a
m
in
ol
ev
ul
in
ic
ac
id
d
eh
yd
ra
ta
se
1
Q
9D
C
W
4
E
tf
b
E
le
ct
ro
n
tr
an
sf
er
fla
vo
p
ro
te
in
su
b
un
it
b
et
a
1
Q
9D
C
W
4
E
tf
b
E
le
ct
ro
n
tr
an
sf
er
fla
vo
p
ro
te
in
su
b
un
it
b
et
a
1
P
42
12
5
E
ci
1
E
no
yl
-C
oA
d
el
ta
is
om
er
as
e
1,
m
ito
.
1
P
42
12
5
E
ci
1
E
no
yl
-C
oA
d
el
ta
is
om
er
as
e
1,
m
ito
.
1
P
16
85
8
G
ap
d
h
G
ly
ce
ra
ld
eh
yd
e-
3-
p
ho
sp
ha
te
d
eh
yd
ro
ge
na
se
2
Q
05
81
6
Fa
b
p
5
Fa
tt
y
ac
id
-b
in
d
in
g
p
ro
te
in
,
ep
id
er
m
al
1
Q
9E
T0
1
P
yg
l
G
ly
co
ge
n
p
ho
sp
ho
ry
la
se
,
liv
er
fo
rm
1
B
0R
1E
3
H
in
t1
H
is
tid
in
e
tr
ia
d
nu
cl
eo
tid
e-
b
in
d
in
g
p
ro
te
in
1
1
B
8J
K
32
H
nr
np
m
H
et
er
og
en
eo
us
nu
cl
ea
r
rib
on
uc
le
op
ro
te
in
M
2
D
3Z
63
6
P
p
a2
In
or
ga
ni
c
p
yr
op
ho
sp
ha
ta
se
2,
m
ito
.
1
Q
9D
0S
9
H
in
t2
H
is
tid
in
e
tr
ia
d
nu
cl
eo
tid
e-
b
in
d
in
g
p
ro
te
in
2,
m
ito
.
2
Q
9D
6R
2
Id
h3
a
Is
oc
itr
at
e
d
eh
yd
ro
ge
na
se

N
A
D

su
b
un
it
al
p
ha
,
m
ito
.
1
Q
9D
81
9
P
p
a1
In
or
ga
ni
c
p
yr
op
ho
sp
ha
ta
se
2
P
16
12
5
Ld
hb
L-
la
ct
at
e
d
eh
yd
ro
ge
na
se
B
ch
ai
n
1
Q
8B
W
T1
A
ca
a2
3-
ke
to
ac
yl
-C
oA
th
io
la
se
,
m
ito
.
1
Q
9C
X
T8
P
m
p
cb
M
ito
ch
on
d
ria
l-
p
ro
ce
ss
in
g
p
ep
tid
as
e
su
b
un
it
b
et
a
1
P
53
39
5
D
b
t
Li
p
oa
m
id
e
ac
yl
tr
an
sf
er
as
e
co
m
p
on
en
t
of
b
ra
nc
he
d
-
ch
ai
n
al
p
ha
-k
et
o
ac
id
d
eh
yd
ro
ge
na
se
co
m
p
le
x,
m
ito
.
1
O
88
49
2
P
lin
4
P
er
ili
p
in
-4
1
P
16
12
5
Ld
hb
L-
la
ct
at
e
d
eh
yd
ro
ge
na
se
B
ch
ai
n
1
P
17
75
1
Tp
i1
Tr
io
se
p
ho
sp
ha
te
is
om
er
as
e
1
Q
9E
Q
20
A
ld
h6
a1
M
et
hy
lm
al
on
at
e-
se
m
ia
ld
eh
yd
e
d
eh
yd
ro
ge
na
se

a
cy
la
tin
g
,
m
ito
.
1
B
io
lo
gi
ca
lA
d
he
si
on
Q
9J
LZ
3
A
uh
M
et
hy
lg
lu
ta
co
ny
l-
C
oA
hy
d
ra
ta
se
,
m
ito
.
1
Q
04
85
7
C
ol
6a
1
C
ol
la
ge
n
al
p
ha
-1
(V
I)
ch
ai
n
1
Q
9C
R
61
N
d
uf
b
7
N
A
D
H
d
eh
yd
ro
ge
na
se

u
b
iq
ui
no
ne

1
b
et
a
su
b
co
m
p
le
x
su
b
un
it
7
2
P
08
12
2
C
ol
4a
2
C
ol
la
ge
n
al
p
ha
-2
(IV
)
ch
ai
n
1
Q
8B
M
F3
M
e3
N
A
D
P
-d
ep
en
d
en
t
m
al
ic
en
zy
m
e,
m
ito
.
1
Q
99
K
47
Fg
a
Fi
b
rin
og
en
,
al
p
ha
p
ol
yp
ep
tid
e
1
Q
8R
5J
9
A
rl6
ip
5
P
R
A
1
fa
m
ily
p
ro
te
in
3
2
E
9P
W
Q
3
C
ol
6a
3
P
ro
te
in
C
ol
6a
3
1
P
62
19
2
P
sm
c1
26
S
p
ro
te
as
e
re
gu
la
to
ry
su
b
un
it
4
(R
p
t2
)
2
M
ul
tic
el
lu
la
r
O
rg
an
is
m
al
P
ro
ce
ss
Q
9R
1P
4
P
sm
a1
P
ro
te
as
om
e
su
b
un
it
al
p
ha
ty
p
e-
1
(
6)
2
Q
6Z
W
Q
9
M
yl
12
a
M
yo
si
n,
lig
ht
ch
ai
n
12
A
,
re
gu
la
to
ry
,
no
n-
sa
rc
om
er
ic
1
Q
9D
B
15
M
rp
l1
2
39
S
rib
os
om
al
p
ro
te
in
L1
2,
m
ito
.
1
D
ev
el
op
m
en
ta
lP
ro
ce
ss
P
60
86
7
R
p
s2
0
40
S
rib
os
om
al
p
ro
te
in
S
20
2
Q
8V
D
Q
1–
2
P
tg
r2
P
ro
st
ag
la
nd
in
re
d
uc
ta
se
2,
Is
of
or
m
2
Q
62
41
7–
4
S
or
b
s1
S
or
b
in
an
d
S
H
3
d
om
ai
n-
co
nt
ai
ni
ng
p
ro
te
in
1,
Is
of
or
m
4
2
B
io
lo
gi
ca
lR
eg
ul
at
io
n
P
35
23
5–
2
P
tp
n1
1
Ty
ro
si
ne
-p
ro
te
in
p
ho
sp
ha
ta
se
no
n-
re
ce
p
to
r
ty
p
e
11
,
Is
of
or
m
2
2
Q
99
P
T1
A
rh
gd
ia
R
ho
G
D
P
-d
is
so
ci
at
io
n
in
hi
b
ito
r
1
1
B
io
lo
gi
ca
lA
d
he
si
on
Q
60
85
4
S
er
p
in
b
6
S
er
p
in
B
6
1
P
11
08
7
C
ol
1a
1
C
ol
la
ge
n
al
p
ha
-1
(I)
ch
ai
n
2
A
p
op
to
tic
P
ro
ce
ss
Q
01
14
9
C
ol
1a
2
C
ol
la
ge
n
al
p
ha
-2
(I)
ch
ai
n
2
D
3Y
X
27
H
tr
a2
S
er
in
e
p
ro
te
as
e
H
TR
A
2,
m
ito
.
1
M
ul
tic
el
lu
la
r
O
rg
an
is
m
al
P
ro
ce
ss
C
el
lu
la
r
P
ro
ce
ss
Q
3U
H
68
–2
Li
m
ch
1
LI
M
an
d
ca
lp
on
in
ho
m
ol
og
y
d
om
ai
ns
-c
on
ta
in
in
g
p
ro
te
in
1,
Is
of
or
m
2
2
B
sg
B
as
ig
in
1
Q
62
00
0
O
gn
M
im
ec
an
2
P
05
13
2–
2
P
rk
ac
a
cA
M
P
-d
ep
en
d
en
t
p
ro
te
in
ki
na
se
ca
ta
ly
tic
su
b
un
it

,
Is
of
or
m
2
1
D
ev
el
op
m
en
ta
lP
ro
ce
ss
D
3Z
63
0
M
yl
k3
M
yo
si
n
lig
ht
ch
ai
n
ki
na
se
3
1
Q
80
X
90
Fl
nb
Fi
la
m
in
-B
2
Q
91
Y
Z
8
P
ab
p
c4
P
ol
y(
A
)
b
in
d
in
g
p
ro
te
in
,
cy
to
p
la
sm
ic
4
1
A
2A
E
X
7
A
2A
E
X
8
Fh
l1
Fo
ur
an
d
a
ha
lf
LI
M
d
om
ai
ns
p
ro
te
in
1
2
P
67
77
8
P
hb
P
ro
hi
b
iti
n
1
O
70
43
3
Fh
l2
Fo
ur
an
d
a
ha
lf
LI
M
d
om
ai
ns
p
ro
te
in
2
2
P
26
03
9
Tl
n1
Ta
lin
-1
1
Q
9J
K
92
H
sp
b
8
H
ea
t
sh
oc
k
p
ro
te
in
b
et
a-
8
2
C
el
lu
la
r
C
om
p
on
en
t
O
rg
an
iz
at
io
n
or
B
io
ge
ne
si
s
B
io
lo
gi
ca
lR
eg
ul
at
io
n
P
26
04
0
E
zr
E
zr
in
1
Q
06
89
0
C
lu
C
lu
st
er
in
2
P
68
43
3
H
is
t1
h3
a
H
is
to
ne
H
3.
1
1
Q
9J
K
S
4–
2
Ld
b
3
LI
M
d
om
ai
n-
b
in
d
in
g
p
ro
te
in
3,
Is
of
or
m
2
2
P
14
73
3
Lm
nb
1
La
m
in
-B
1
1
Lo
ca
liz
at
io
n
Q
62
26
1–
2
S
p
tb
n1
S
p
ec
tr
in
b
et
a
ch
ai
n,
no
n-
er
yt
hr
oc
yt
ic
1,
Is
of
or
m
2
1
Q
9D
C
C
8
To
m
m
20
M
ito
ch
on
d
ria
li
m
p
or
t
re
ce
p
to
r
su
b
un
it
TO
M
20
ho
m
ol
og
2
Proteomic Signatures of Two FHC Animal Models
Molecular & Cellular Proteomics 15.6 1967
TA
B
LE
I—
co
nt
in
ue
d
P
ro
te
in
s
w
hi
ch
ar
e
d
iff
er
en
tia
lly
ex
p
re
ss
ed
in
he
ar
ts
fr
om
3
m
on
th
ol
d
w
ild
-t
yp
e,
R
27
8C
an
d
I7
9N
m
ic
e,
gr
ou
p
ed
ac
co
rd
in
g
to
ge
ne
on
to
lo
gy
(G
O
)b
io
lo
gi
ca
lp
ro
ce
ss
.D
et
ai
ls
of
p
ro
te
in
ex
p
re
ss
io
n
ar
e
sh
ow
n
in
su
p
p
le
m
en
ta
lT
ab
le
S
2.
A
b
b
re
vi
at
io
ns
:
m
ito
,
m
ito
ch
on
d
ria
l
I7
9N
ve
rs
us
W
T
R
27
8C
ve
rs
us
W
T
P
ro
te
in
ID
G
en
e
N
am
e
P
ro
te
in
N
am
e
P
ro
te
in
ID
G
en
e
N
am
e
P
ro
te
in
N
am
e
Im
m
un
e
S
ys
te
m
P
ro
ce
ss
C
el
lu
la
r
P
ro
ce
ss
P
01
02
9
C
4b
C
om
p
le
m
en
t
C
4-
B
1
P
84
07
8
A
rf
1
A
D
P
-r
ib
os
yl
at
io
n
fa
ct
or
1
2
P
63
02
8
Tp
t1
Tr
an
sl
at
io
na
lly
-c
on
tr
ol
le
d
tu
m
or
p
ro
te
in
1
Q
9C
X
J4
A
b
cb
8
A
TP
-b
in
d
in
g
ca
ss
et
te
su
b
-f
am
ily
B
m
em
b
er
8,
m
ito
.
2
N
o
G
O
B
io
lo
gi
ca
lP
ro
ce
ss
Q
9D
7X
Q
3V
2Y
9
D
us
p
3
D
ua
ls
p
ec
ifi
ci
ty
p
ro
te
in
p
ho
sp
ha
ta
se
3
1
P
08
22
6
A
p
oe
A
p
ol
ip
op
ro
te
in
E
1
P
16
04
5
Lg
al
s1
G
al
ec
tin
-1
2
Q
91
W
S
0
C
is
d
1
C
D
G
S
H
iro
n-
su
lfu
r
d
om
ai
n-
co
nt
ai
ni
ng
p
ro
te
in
1
1
Q
61
01
1
G
nb
3
G
ua
ni
ne
nu
cl
eo
tid
e-
b
in
d
in
g
p
ro
te
in
G
(I)
/G
(S
)/
G
(T
)
su
b
un
it
b
et
a-
3
2
E
9Q
4B
5
C
cd
c5
8
C
oi
le
d
-c
oi
ld
om
ai
n-
co
nt
ai
ni
ng
p
ro
te
in
58
1
Q
6U
R
W
6–
2
M
yh
14
M
yo
si
n-
14
,
Is
of
or
m
2
2
Q
9C
P
Q
1
C
ox
6c
C
yt
oc
hr
om
e
c
ox
id
as
e
su
b
un
it
6C
1
Q
3U
IZ
8–
2
M
yl
k3
M
yo
si
n
lig
ht
ch
ai
n
ki
na
se
3,
Is
of
or
m
2
2
P
05
06
3
A
ld
oc
Fr
uc
to
se
-b
is
p
ho
sp
ha
te
al
d
ol
as
e
C
1
P
26
64
5
M
ar
ck
s
M
yr
is
to
yl
at
ed
al
an
in
e-
ric
h
C
-k
in
as
e
su
b
st
ra
te
2
Q
9Q
U
H
0
G
lrx
G
lu
ta
re
d
ox
in
-1
1
P
68
25
4
Y
w
ha
q
14
–3
-3
p
ro
te
in
th
et
a
2
P
10
64
9
G
st
m
1
G
lu
ta
th
io
ne
S
-t
ra
ns
fe
ra
se
M
u
1
1
P
61
98
2
Y
w
ha
g
14
–3
-3
p
ro
te
in
ga
m
m
a
2
Q
91
V
64
Is
oc
1
Is
oc
ho
ris
m
at
as
e
d
om
ai
n-
co
nt
ai
ni
ng
p
ro
te
in
1
1
F6
U
IT
9
P
p
p
1r
12
b
P
ro
te
in
p
ho
sp
ha
ta
se
1
re
gu
la
to
ry
su
b
un
it
12
B
2
P
99
02
9–
2
P
rd
x5
Is
of
or
m
cy
to
p
la
sm
ic

p
er
ox
is
om
al
of
P
er
ox
ire
d
ox
in
-5
,
m
ito
.
1
P
62
07
1
R
ra
s2
R
as
-r
el
at
ed
p
ro
te
in
R
-R
as
2
2
P
20
02
9
H
sp
a5
78
kD
a
gl
uc
os
e-
re
gu
la
te
d
p
ro
te
in
1
Q
8C
C
35
–2
S
yn
p
o
S
yn
ap
to
p
od
in
,
Is
of
or
m
2
2
P
34
88
4
M
if
M
ac
ro
p
ha
ge
m
ig
ra
tio
n
in
hi
b
ito
ry
fa
ct
or
1
P
21
10
7–
2
Tp
m
3
Tr
op
om
yo
si
n
al
p
ha
-3
ch
ai
n,
Is
of
or
m
2
2
E
9Q
7L
0
O
gd
hl
O
xo
gl
ut
ar
at
e
d
eh
yd
ro
ge
na
se
-l
ik
e
1
O
70
37
3
X
irp
1
X
in
ac
tin
-b
in
d
in
g
re
p
ea
t-
co
nt
ai
ni
ng
p
ro
te
in
1
Q
9D
1G
1
R
ab
1b
R
as
-r
el
at
ed
p
ro
te
in
R
ab
-1
B
1
C
el
lu
la
r
C
om
p
on
en
t
O
rg
an
iz
at
io
n
or
B
io
ge
ne
si
s
E
9Q
3Y
1
E
9Q
0P
9
S
er
p
in
b
6a
S
er
p
in
B
6
1
P
61
16
1
A
ct
r2
A
ct
in
-r
el
at
ed
p
ro
te
in
2
2
O
54
98
8–
2
S
lk
S
TE
20
-l
ik
e
se
rin
e/
th
re
on
in
e-
p
ro
te
in
ki
na
se
,
Is
of
or
m
2
1
E
9Q
55
7
D
sp
D
es
m
op
la
ki
n
2
P
80
31
4
C
ct
2
T-
co
m
p
le
x
p
ro
te
in
1
su
b
un
it
b
et
a
1
P
47
75
4
C
ap
za
2
F-
ac
tin
-c
ap
p
in
g
p
ro
te
in
su
b
un
it
al
p
ha
-2
2
Q
9C
Q
N
6
Tm
em
14
c
Tr
an
sm
em
b
ra
ne
p
ro
te
in
1
4
C
1
F8
W
IX
8
H
is
t1
h2
al
H
is
to
ne
H
2A
2
E
0C
Z
27
H
3f
3a
H
is
to
ne
H
3
2
P
68
43
3
H
is
t1
h3
a
H
is
to
ne
H
3.
1
1
P
43
27
4
H
is
t1
h1
e
H
is
to
ne
H
1.
4
2
E
9P
U
M
4
Q
71
LX
4
Tl
n2
Ta
lin
-2
2
N
o
G
O
B
io
lo
gi
ca
l
P
ro
ce
ss
Q
9C
Q
R
4
A
co
t1
3
A
cy
l-
co
en
zy
m
e
A
th
io
es
te
ra
se
13
1
Q
9D
C
X
2
A
tp
5h
A
TP
sy
nt
ha
se
su
b
un
it
d
,
m
ito
.
Q
8V
B
T1
Tx
ln
b
B
et
a-
ta
xi
lin
2
Q
5S
X
R
6
C
ltc
C
la
th
rin
he
av
y
ch
ai
n
2
G
3U
X
44
H
2-
K
e6
E
st
ra
d
io
l1
7-
b
et
a-
d
eh
yd
ro
ge
na
se
8
1
Q
9D
C
M
2
G
st
k1
G
lu
ta
th
io
ne
S
-t
ra
ns
fe
ra
se
ka
p
p
a
1
1
K
3W
4S
6
G
yg
G
ly
co
ge
ni
n-
1
2
P
17
87
9
H
sp
a1
b
H
ea
t
sh
oc
k
70
kD
a
p
ro
te
in
1B
1
Q
9E
S
B
3
H
rg
H
is
tid
in
e-
ric
h
gl
yc
op
ro
te
in
2
Q
8K
31
0
M
at
r3
M
at
rin
-3
2
Q
9Q
Y
A
2
To
m
m
40
M
ito
ch
on
d
ria
li
m
p
or
t
re
ce
p
to
r
su
b
un
it
TO
M
40
ho
m
ol
og
2
P
63
03
0
M
p
c1
M
ito
ch
on
d
ria
lp
yr
uv
at
e
ca
rr
ie
r
1
Q
99
JI
4
P
sm
d
6
26
S
p
ro
te
as
om
e
no
n-
A
TP
as
e
re
gu
la
to
ry
su
b
un
it
6
(R
p
n7
)
2
Q
9D
1G
1
R
ab
1b
R
as
-r
el
at
ed
p
ro
te
in
R
ab
-1
B
2
P
53
99
4
R
ab
2a
R
as
-r
el
at
ed
p
ro
te
in
R
ab
-2
A
2
P
61
02
7
R
ab
10
R
as
-r
el
at
ed
p
ro
te
in
R
ab
-1
0
2
Q
4V
A
E
3
Tm
em
65
Tr
an
sm
em
b
ra
ne
p
ro
te
in
65
1
Proteomic Signatures of Two FHC Animal Models
1968 Molecular & Cellular Proteomics 15.6
some metabolizes many cellular proteins, and has been
shown to play a role in lipid metabolism (41, 42). The Ubiquitin
Proteasome System (UPS) has also been shown to regulate
5-AMP-activated protein kinase (AMPK), a key enzyme in
regulating cellular energy homeostasis (43). A total of 23 pro-
teasome subunits were identified in this investigation. Four
proteasome subunits showed a significant decrease in R278C
mice relative to WT hearts (supplemental Table S3). When
these 23 proteasome subunits were compared between
R278C and I79N hearts, 9 subunits were found to be signifi-
cantly higher in I79N hearts than R278C hearts. Expression of
3 proteasome subunits was also lower in R278C hearts than
WT hearts. Hence the results from the label-free proteomic
approach suggest that the proteasome is differentially regu-
lated in R278C and I79N mouse hearts. To confirm the differ-
ences in proteasome levels detected by mass spectrometry,
we examined the expression of a subset of proteasome sub-
units in R278C and I79N hearts (Fig. 2). Expression of two
subunits of the 20S proteasome, 1 (PSMA6) and 1, was
measured in total and cytosolic cardiac homogenates (Fig. 2).
In total homogenates, 1 expression was 20% higher in I79N
hearts than WT hearts, and expression of both subunits was
higher in I79N hearts than R278C hearts (Fig. 2). Hearts from
R278C mice showed a trend toward lower total 1 and 1
levels relative to WT; however, these differences were not
statistically significant (p  0.217 and 0.156 respectively).
Expression of these subunits in cytosolic cardiac homoge-
nates was also investigated, yielding similar results. Expres-
sion of 1 and 1 was higher in I79N cytosolic heart fractions
than R278C cytosolic heart fractions, and decreased in
R278C hearts relative to WT hearts by 41 and 21%, respec-
tively (Fig. 2). A trend toward increased expression of 1 and
1 in I79N hearts relative to WT hearts was observed; how-
ever these differences were not statistically significant (p 
0.289 and 0.139 respectively). Expression of the 20S subunit
2 was also examined in cytosolic heart fractions, showing
lower expression in R278C hearts and higher expression in
I79N than R278C hearts (Fig. 3).
The expression of four subunits of the 19S regulatory par-
ticle was also examined: Rpt1, Rpt4, Rpt6, and Rpn2, as well
as PA28, a subunit of the 11S regulatory particle (Figs. 2 and
3). A similar trend to 20S expression was observed in 19S
subunit expression; expression of three out of the four sub-
units (Rpt4, Rpt6, and Rpn2) was decreased in R278C hearts
compared with WT hearts, and expression of all four subunits
examined was higher in I79N hearts than R278C hearts (Figs.
FIG. 2. Validation of increased proteasome subunit expression in hearts from I79Nmice relative to R278C hearts by Western blotting.
Western blots of proteasome levels (1/PSMA6, 1, Rpt4) and total protein (Stain-Free, used as loading controls) and corresponding
semiquantitative bar graphs are shown. A, Determination of proteasome amount in total cardiac homogenates (n  4). B, Determination of
proteasome amount in cytosolic cardiac homogenates (n  4). *, p  0.05.
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2 and 3). PA28 levels were not affected in R278C hearts or
I79N hearts, in agreement with MS data (Fig. 3). Overall,
expression of proteasome subunits was higher in I79N hearts
than R278C hearts as judged by Western blotting, which is
consistent with the proteomic data (supplemental Table S4).
To further explore the effect of the altered proteasome
levels in the transgenic hearts, the proteolytic activities of the
26S proteasomes were measured (Fig. 4). 26S proteasome
activities are ATP dependent, in contrast to 20S activities, and
the assays are conducted in the presence of ATP to optimize
measurement of the 26S activity only. The 26S and 20S 5
(chymotrypsin-like) activities of the proteasome in the I79N
hearts were significantly lower than in WT and R278C hearts,
suggesting proteasome dysfunction (Fig. 4). The 26S and 20S
5 activities of the R278C hearts were similar to WT hearts.
The 5 activity is the main proteolytic activity of the protea-
some, so it is likely that other components of the proteasome
pathway would be affected. The 26S 1 (caspase-like) activity
of the proteasome was also measured and found to be similar
between the three groups of transgenic hearts. Because we
have previously shown that the immunoproteasome is impor-
tant for the removal of oxidized proteins, the immunoprotea-
some 1i and 5i activities were determined (35, 36) (Fig. 4).
Although the immunoproteasome 1i activity was decreased
in both I79N and R278C hearts relative to control hearts, the
5i activity was only decreased in the I79N hearts. The 1i
activity was the only type of proteasome activity that we
determined to be decreased in R278C hearts. To determine if
other cytosolic proteolytic enzymes such as calpain were also
affected in I79N hearts, calpain activity was determined and
found to be similar between all hearts investigated (Fig. 4).
In addition to its roles in signaling and intracellular traffick-
ing, ubiquitination is important as a signal for protein degra-
dation, and decreases in proteasome function and/or dys-
regulation of the ubiquitination pathway have been linked to
up-regulation of stress related proteins, increases in polyu-
biquinated proteins, and increased oxidative stress (44, 45).
To determine if impaired proteasome function is associated
with increased ubiquitination, heart lysates were electro-
phoresed and probed with an anti-ubiquitin antibody. Levels
of ubiquitinated proteins in total homogenates and oxidized
proteins in cytosolic homogenates (as determined using the
OxyBlot procedure, which detects carbonylated proteins)
were increased in I79N mice relative to WT and R278C mice,
consistent with impaired UPS function (Figs. 4 and 5). Inter-
estingly, the levels of oxidized proteins in cytosolic homoge-
nates were lower in R278C hearts than in WT and I79N hearts
(Fig. 5).
FIG. 3. Determination of proteasome amount in cytosolic fractions from wild-type, R278C, and I79N mouse hearts. Western blots of
proteasome levels (2, Rpt1, Rpt6, Rpn2, PA28) and total protein (Stain-Free, used as loading controls) and corresponding semi-quantitative
bar graphs are shown (n  3–4). *, p  0.05.
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Antioxidant Defense System—The proteomic data also sug-
gests that several antioxidant enzymes including thiore-
doxin-1 (TRX-1) and glutathione S-transferase mu 1 (GSTM1)
were up-regulated in I79N hearts compared with R278C
hearts, and GSTM1 and Isoform cytoplasmicperoxisomal of
Peroxiredoxin-5, mitochondrial were up-regulated in I79N
compared with WT hearts (supplemental Table S5). To further
investigate the expression of stress-related proteins that may
be affected in R278C or I79N hearts, TRX-1, GSTM1 and one
chaperone [heat shock protein 60 (Hsp60)] were selected for
Western blotting. TRX-1 is a mainly cytosolic antioxidant en-
zyme that reduces oxidized proteins, and thus plays an im-
portant role in protecting against oxidative stress (46). Oxida-
tive stress and other types of cellular stresses have been
shown to upregulate thioredoxin expression (47–49). Western
blotting showed that TRX-1 was significantly up-regulated in
I79N hearts relative to R278C hearts, consistent with the
proteomic results (Fig. 6). GSTM1 is an antioxidant enzyme
that also plays a role in coping with oxidative stress by con-
jugating the antioxidant glutathione to target proteins (50).
GSTM1 expression was found to be increased in I79N hearts
when compared with WT and R278C hearts by proteomic
analysis. Western blotting showed a trend toward increased
GSTM1 expression in I79N hearts relative to WT hearts, but
this increase was not statistically significant (p  0.075).
Hsp60 is a mitochondrial chaperone that is implicated in
mitochondrial import, proper folding of imported proteins, and
promoting refolding of improperly folded proteins under
stress conditions (51, 52). Protein expression of Hsp60 was
not altered in R278C or I79N hearts, in agreement with the
proteomic data (Fig. 6).
Increases in antioxidant enzymes are typically associated
with increased total antioxidant capacity of the tissue. Meas-
uring the antioxidant capacity of the cardiac homogenates
showed that the antioxidant capacity was nearly doubled in
I79N hearts relative to WT hearts (increased by 95%), sug-
gesting that antioxidant levels are up-regulated to compen-
sate for increased oxidative stress (Fig. 6D). These findings all
suggest that oxidative stress is higher in I79N hearts.
Energy Production Pathways—Proteomic results also sug-
gest that several glycolytic, tricarboxylic acid cycle (TCA) and
electron transport chain (ETC) enzymes are up-regulated in
I79N hearts compared with WT and R278C hearts (supple-
mental Tables S2, S3, and S6). Some of the enzymes up-
regulated in I79N hearts relative to WT and R278C hearts in
glycolytic, TCA and ETC pathways include triosephosphate
isomerase, fructose-bisphosphate aldolase C, isocitrate de-
hydrogenase [NAD] subunit alpha (mitochondrial), oxogl-
utarate dehydrogenase-like, and cytochrome c oxidase sub-
units 6A and 6C. To further confirm the importance and
involvement of these pathways, the levels of metabolites (in-
termediates and products of metabolism) present in these
hearts were determined by GC-TOF (Figs. 7 and 8, Table II,
supplemental Table S8). Mass spectra of representative sin-
gle peptides for which significant changes were observed are
shown in supplemental Fig. S4.
FIG. 4. Characterization of proteolytic activity and ubiquitination in wild-type, R278C, and I79N mouse hearts. A, 26S proteasome
activity of lysates of I79N, R278C, and wild-type mouse hearts (n  3). B, 20S proteasome activity of lysates of wild-type, R278C, and I79N
mouse hearts (n  3). C, Western blot of free ubiquitin levels and ubiquinated proteins in transgenic mouse hearts (n  3). D, Calpain activity
(n  3). *, p  0.05. **, p  0.001.
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Metabolomic Results—The metabolome consists of all of
the metabolites, including substrates, intermediates and
products of metabolic reactions within the cell. As the end-
products of metabolic reactions, the metabolome can be
indicative of the overall health of the cell, and offer useful
information on the dysregulation of certain pathways. Similar
to the results of the proteomic study, more metabolites were
differentially expressed in R278C hearts when compared with
WT hearts (46 changed of 304 identified metabolites) than
when I79N hearts were compared with WT hearts (21
changed of 304 identified), strongly suggesting that the rela-
tive number of proteins or metabolites differentially expressed
were not major factors with respect to the resulting pheno-
type. When R278C and I79N hearts were directly compared,
17 metabolites were changed.
Pathway analysis of the metabolomics data using Metabo-
Analyst 2.0, a comprehensive suite of web tools for metabo-
lomic data processing, visualization and analysis (53), showed
that two pathways were significantly affected in R278C hearts
compared with WT hearts: biosynthesis of unsaturated fatty
acids and fatty acid synthesis, and two other pathways bor-
dered on significance (Fig. 7). Although several metabolites
were altered in I79N hearts relative to WT hearts no pathway
was statistically significantly affected. One pathway that bor-
dered on significance in I79N versus hearts was starch and
sucrose metabolism (Fig. 7). Comparison of I79N and R278C
hearts revealed the greatest number of significant differences,
with four pathways affected (supplemental Fig. S2). These
were aminoacyl-tRNA biosynthesis, cyanoamino acid me-
tabolism, nitrogen metabolism, and methane metabolism,
which were up-regulated in R278C hearts relative to I79N
hearts (supplemental Fig. S2). Many unknown metabolites
were also detected and quantified and shown in the sup-
plemental Table S8.
Metabolomic analysis showed that the levels of eight fatty
acids were increased in R278C hearts relative to WT hearts,
compared with one fatty acid that was decreased in I79N
hearts compared with WT hearts. Increased levels of creati-
nine in I79N hearts relative to WT hearts (Fig. 8) as well as
other changes in metabolites associated with energy metab-
olism (Table II) suggest impaired energy production in I79N
hearts. R278C hearts showed decreases in glucose-6-phos-
phate, fructose-6-phosphate, and hexose-6-phosphate when
compared with WT hearts, whereas the I79N hearts showed a
trend toward increased levels of these metabolites as well as
increased fructose levels in comparison to WT hearts (Fig. 8
and supplemental Fig. S3). This trend of increased levels of
FIG. 5. Characterization of levels of oxidized proteins in wild-type, R278C, and I79N mouse hearts. A, Oxidized protein levels in
cytosolic heart lysates from 3 month old hearts were determined by the Oxyblot method. Carbonyl residues were derivatized with DNPH and
subsequently detected by Western blotting using anti-DNP antibody (n  4). B) Oxidized proteins in total heart lysates from 3 month old hearts
(n  4). *, p  0.05. **, p  0.001.
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glycolytic metabolites in I79N hearts relative to both WT and
R278C hearts is consistent with the proteomics findings (in-
creased levels of glycolytic enzymes) which suggest that gly-
colysis may be accelerated in I79N hearts. A summary of the
proteins and metabolites found to be differentially expressed
in the glycolytic pathway are shown in Fig. 9.
DISCUSSION
FHC-causing TnT mutations are associated with a high risk
of sudden cardiac death, and the mechanisms underlying the
disease are not well understood. Transgenic mice expressing
the I79N mutation have low exercise tolerance and die upon
isoproterenol treatment, whereas R278C mice are tolerant of
exercise and isoproterenol treatment (54, 55). We used pro-
teomic and metabolomic approaches to uncover pathways
affected in TnT-related FHC. The only previous proteomic
approach to investigate FHC models was using two-dimen-
sional polyacrylamide gel electrophoresis (2DE) coupled with
a Q-TOF Ultima MS (56). Mice predisposed to developing
hypertrophic cardiomyopathy (HCM) due to overexpression of
mutated (Gly203Ser [G203S]) troponin I (TnI) were studied by
2DE coupled with LC-MS/MS to identify protein spots that
showed altered expression. This study identified 34 protein
spots (corresponding to 22 different proteins) that showed at
least a 2-fold change in G203S hearts relative to WT hearts
(56). Altered proteins in the G203S hearts were involved in
energy production and utilization (e.g. NADH dehydrogenase),
calcium handling (e.g. S100 calcium binding protein A10), and
cell structure and muscle contraction (e.g. myosin) (56). 2DE
and mass spectrometry have also been used in studies on
FIG. 6. Characterization of levels of oxidative stress-related proteins and antioxidant capacity in wild-type, R287C, and I79N mouse
hearts. Western blot of enzymes associated with oxidative stress, A, Thioredoxin-1 (TRX-1) and B, Glutathione S-transferase mu 1 (GSTMI).
C, Western blot of heat shock protein 60 (HSP60), which was not found to be differentially expressed by proteomic methods. D, Antioxidant
capacity of cardiac homogenates were carried out using 2,2-azino-bis(3-ethylbenzthiazoline-6-sulfonic acid) (ABTS)/metmyoglobin. Antiox-
idant activity is measured relative to the antioxidant Trolox and reported in Trolox Equivalent Units (n  4). *, p  0.05.
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human patients and mouse models of dilated cardiomyopathy
(DCM). A study using shotgun LC-MS/MS to compare protein
expression in DCM mouse hearts to WT mouse hearts
showed altered levels of proteins involved in the endoplasmic
reticulum (ER) stress response, cytoskeletal remodeling, and
apoptosis (57). Proteomic investigation of DCM by other
groups found changes in expression of metabolic enzymes
(58–61), stress response proteins (58, 60, 61), and proteins
FIG. 7. Pathway analysis of the metabolomic data comparing wild-type, R278C, and I79N hearts. Pathway analysis was carried out
using MetaboAnalyst 2.0 (92).
FIG. 8. Effect of R278C and I79N mu-
tations on metabolite levels in trans-
genic hearts. Changes in metabolite
levels in WT, R278C, and I79N hearts.
Bar charts for stearic acid, arachidic
acid, heptadecanoic acid, creatinine,
glucose-6-phosphate, and fructose-6-
phosphate are shown. *, p  0.05. **,
p  0.001.
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involved in cell structure and contraction (58, 59). Although
2DE is a powerful technique, it has several disadvantages
including the low dynamic protein range and limitations on the
isoelectric point and molecular weights of proteins that can be
resolved and analyzed. The investigation of the I79N and
R278C hearts using MS suggests that TnT-related car-
diomyopathies are more complex than previous proteomic
and metabolomic studies on cardiomyopathy hearts showed.
More pathways were found to be affected, including path-
ways that have not previously been shown to be affected in
any FHC model.
Proteins Involved in Protein Degradation—Proteomic anal-
ysis revealed changes in expression of several proteasome
subunits. Several of the proteasome subunits identified by
mass spectrometry showed significantly higher levels in I79N
mice than R278C mice (9 of 23) and some showed decreases
in R278C relative to WT (3 of 23). Validation of these findings
by Western blotting revealed a similar trend; expression of
proteasome subunits was decreased in R278C hearts and
increased in I79N hearts in one case, and was consistently
higher in I79N than R278C hearts (Figs. 3 and 4). Further
investigation of the proteasome revealed that 5 (chymotryp-
sin-like) proteasome activity was decreased in I79N mice
relative to WT and R278C mice (Fig. 4). Thus, despite higher
proteasome subunit expression in I79N than R278C hearts,
both 20S and 26S chymotrypsin-like activities are decreased,
indicating proteasome impairment. 20S proteasome activity
was measured because the 20S proteasome has been shown
to degrade oxidized proteins independently of ATP. Lower
20S activities would be expected to result in higher levels of
oxidized proteins. The immunoproteasome activity was also
affected; the 1i activity was decreased in R278C and I79N
hearts, and 5i activity was decreased in I79N hearts. Immu-
noproteasome activity has not been previously measured in
hearts, and these results suggest that the immunoproteasome
function is impaired in I79N hearts relative to WT hearts.
Accumulation of ubiquitinated and oxidized proteins, typi-
cal indicators of proteasome impairment, was investigated to
see if they were affected in I79N or R278C mice. Western
blots showed a greater accumulation of ubiquitinated proteins
in total homogenates and oxidized proteins in cytosolic frac-
tions from I79N hearts relative to WT and R278C, consistent
with impaired proteasome function (Figs. 4 and 5). The in-
creased level of oxidized proteins is consistent with impaired
immunoproteasome activity in I79N hearts. Increased levels
of polyubiqutinated proteins are usually associated with in-
creased levels of oxidized proteins, an independent indicator
of increased oxidative stress. With up-regulated antioxidant
enzymes and antioxidant capacity, it is likely that the intracel-
lular homeostasis in I79N heart cells is significantly compro-
mised. Increased levels of oxidized proteins suggest that
oxidative stress in cytosolic cardiac homogenates is in-
creased in I79N mice relative to WT and R278C hearts. Levels
of oxidized proteins in total homogenates were similar in I79N,
R278C and WT hearts, indicating that oxidative stress may be
predominantly in the cytosol (Fig. 5). Overall, I79N hearts,
which serve as a model of TnT-related cardiomyopathy with a
poor prognosis, displayed higher levels of oxidative stress,
increased ubiquitination, and an increase in proteasome sub-
TABLE II
Metabolites which are differentially expressed in hearts from 3 month
old wild-type, R278C and I79N mice grouped according to type of
metabolite. Details of metabolite expression are shown in supplemen-
tal Table S7
R278C vs. WT I79N vs. WT I79N vs. R278C
Metabolite Metabolite Metabolite
Fatty Acids Fatty Acids Fatty Acids
Arachidic acid 1 cis-gondoic acid 1 Heptadecanoic acid 2
Capric acid 1 Sugars Sugars
cis-gondoic acid 1 1,5-anhydroglucitol 1 1,5-anhydroglucitol 1
Heptadecanoic acid 1 Fructose 1 Sugar Acids
Oleic acid 1 Sugar Alcohols Pentonic acid 1
Palmitic acid 1 Ribitol 1 Ribonic acid 1
Pelargonic acid 1 Methylphenols Vitamins/Derivatives
Stearic acid 1 p-cresol 1 Dehydroascorbic acid 1
Sugars Guanidino Compounds Pantothenic acid 2
Fructose-6-phosphate 2 Creatinine 1 Amino Acids
Glucose-6-phosphate 2 Nucleosides Asparagine 1
Hexose-6-phosphate 2 Thymidine 2 Glycine 1
Maltotriose 2 Other Organic Acids Other Organic Acids
Sugar Alcohols Dehydroabietic acid 1 Uric acid 1
Beta-glycerolphosphate 1 Unknown Metabolites (13) Hydrocarbons
Bisphosphoglycerol 1 110 1 Squalene 2
Xylitol 1 257 1 Unknown Metabolites (7)
Vitamins/Derivatives 2061 1 1760 2
Dehydroascorbic acid 2 3083 1 3200 2
Nicotinamide 1 6104 1 31962 1
Peptides 16561 1 84544 1
Glutathione 2 32153 1 97584 2
Amino Acids 42424 1 100321 1
Aspartic acid 2 430211 102601 1
Glycine 2 842231
Other Organic Acids 97326 1
Benzoic acid 1 100584 1
Gamma-aminobutyric acid 2 100730 1
Malic acid 1
Uric acid 2
Other Organic Alcohols
Methanolphosphate 1
Hydrocarbons
Squalene 1
Methylphenols
p-cresol 1
Unknown Metabolites (19)
54 1
1064 1
1704 1
9320 1
17651 1
17954 1
18485 2
21665 1
21682 1
21683 1
26746 1
33989 1
42424 1
84223 1
84382 2
84682 1
97584 1
100321 2
102601 2
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unit and TRX-1 expression relative to R278C hearts, the mild,
late-onset disease model. Accumulation of ubiquitinated pro-
teins, increases and decreases in proteasome activity, and
changes in expression of the proteasome and associated
proteins have been observed in several experimental and
human heart diseases (62–65). These results suggest that
proteasome dysfunction is an important difference between
the I79N and WT or R278C hearts. Impaired proteasome
function by itself could account for the poor prognosis in I79N
FHC patients, because recent work with pigs showed that
chronic proteasome inhibition led to functional and structural
cardiomyopathic sequelae (66). Proteasome dysfunction has
been previously shown to occur in some but not all hearts
containing MyBPC mutants associated with FHC. This was
because of some MyBPC mutants not being properly de-
graded by the proteasome, resulting in MyBPC aggregates
and insufficient proteasome activity to degrade other sub-
strates (23–26). This possibility needs to be tested with other
thin and thick filament mutations.
Proteins Involved in Metabolism—
Glucose Metabolism—Proteins involved in metabolism ac-
count for the largest group of biological processes affected
when comparing R278C or I79N hearts to WT hearts (Fig. 1).
Some proteins involved in glycolysis were up-regulated in
I79N hearts, whereas expression of the glycolytic enzyme
glyceraldehyde-3-phosphate dehydrogenase was decreased
in R278C hearts (Fig. 9 and supplemental Table S6). Metabo-
lomic analysis revealed several changes in key metabolites
including altered levels of metabolites in the glycolytic path-
way in R278C hearts (Table II and Fig. 9). Another affected
pathway that seems to be important in cardiac physiology is
the galactose pathway. Important components of the galac-
tose pathway, glucose-1-phosphate and raffinose (a trisac-
charide containing galactose), although not statistically sig-
nificant, showed higher levels for all averaged biological
replicates than WT or R278C averaged biological replicates
(supplemental Table S2). Galactose is an epimer of glucose
which can be converted to glucose-6-phosphate, at which
point it may enter the glycolytic pathway. Impaired galactose
metabolism is associated with hypertrophic cardiomyopathy
and heart failure (67, 68). Additionally, mutations in -galac-
tosidase A (a glycoside hydrolase enzyme that catalyzes the
hydrolysis of terminal alpha-galactosyl moieties from glyco-
lipids and glycoproteins) have been shown to phenocopy
hypertrophic cardiomyopathy caused by mutations in sarco-
meric proteins (69–71). Further studies into the galactose
pathway should be carried out in hearts with cardiomyopathy
as this pathway may be important in FHC.
The increased protein expression of hexokinase, aldolase,
and triosphosphate isomerase in I79N hearts relative to
R278C (as determined by mass spectrometry) suggest accel-
erated glycolysis. Enhanced dependence on glucose and ac-
celerated glycolysis have previously been reported in hyper-
trophied hearts (72). Several other previous studies have
demonstrated altered energy metabolism in hypertrophic car-
diomyopathy, and energy depletion due to inefficient sarco-
meric ATP usage has been suggested as an important unify-
ing factor in FHC (73). Previous studies also suggest that a
switch in energy substrate utilization occurs during disease
progression in cardiomyopathies (74).
Impaired energy metabolism has previously been sug-
gested by several groups to be a major contributing factor to
HCM. The majority of the 22 proteins that were altered in TnI
FHC G203S hearts were involved in energy production (56).
The G203S hearts showed up-regulation of several proteins
involved in the tricarboxylic acid cycle (TCA) and the electron
FIG. 9. Changes in levels of metabo-
lites and enzymes in the glycolytic
pathway in R278C and I79N hearts. A
solid black arrow indicates metabolite or
enzyme is increased in I79N hearts rela-
tive to WT and R278C. An empty arrow
indicates that the metabolite or enzyme
is increased in I79N relative to R278C
only. An arrow with gray fill indicates a
decrease in R278C relative to WT. The
galactose pathway is also shown (see
Discussion and supplemental Fig. S3).
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transport chain (ETC), which is consistent with the elevated
TCA and ETC proteins in the I79N hearts. However, the I79N
hearts also showed an up-regulated glycolytic pathway which
was not detected in the TnI G203S hearts. The increased
levels of enzymes in the glycolytic pathway may indicate that
the cell is attempting to produce more ATP. Indeed, it has
been demonstrated that energy metabolism is impaired in
I79N hearts, and inefficient sarcomeric ATP usage is one
factor thought to play a role in the pathogenesis of FHC (73,
75, 76). Interestingly, the ubiquitin-dependent proteolysis per-
formed by the proteasome utilizes ATP, and a decrease in
ATP levels may also decrease protein degradation (77, 78);
therefore it is conceivable that one mechanism by which TnT
mutations affect the proteasome is through ATP depletion.
Altered energetics has been demonstrated in various mod-
els of TnT-related FHC. After six months of daily exercise,
most transgenic rats containing truncated human cardiac
TnT, resulting from an intron 15 splice donor site mutation
observed in FHC patients, showed ventricular tachycardia/
fibrillation and myofibrillar disarray, whereas no transgenic
rats expressing WT TnT showed ventricular tachycardia/fibril-
lation and myofibrillar disarray (79). These truncated TnT
transgenic rats showed impaired cardiac metabolism, de-
creased phosphocreatine levels and decreased phosphocre-
atine to ATP ratios (-31%, p  0.05) (80), although the ATP
levels were not significantly affected. These changes in me-
tabolites were observed even though the basal cardiac pa-
rameters (ejection fraction, end-diastolic volume etc.) of the
transgenic truncated TnT rats were not significantly different
from the control transgenic rats. Another study on energy
utilization in TnT-FHC showed that transgenic hearts with
R92W and R92L TnT mutations both showed greater ATP
utilization during muscle contraction, with the R92W hearts
showing more severe energetic abnormalities and greater
contractile dysfunction than the R92L hearts (81). These
hearts had higher intracellular ADP and Pi levels, as well as
lower ATP and phosphocreatine levels (81). It was shown in
our study that the levels of creatinine were higher in I79N
hearts than WT hearts.
Fatty Acid Metabolism—In the heart, phosphocreatine is
the main source of reserve energy; when ATP demand ex-
ceeds supply, as in acute pump failure or high wall stress,
utilization of phosphocreatine by the creatine kinase system
maintains constant ATP levels to meet the heart’s energy
needs (82). As pathogenesis progresses, the demand for ATP
increases and the level of phosphocreatine is depleted, which
necessitates the use of alternative energy substrates (76, 83).
In the early compensatory stages of cardiomyopathy, the
heart utilizes free fatty acids as an energy substrate, which
yields more ATP than glucose but also requires more oxygen
to metabolize (84). At more advanced stages of disease, as in
heart failure and end-stage HCM, the heart has been shown to
favor glucose over fatty acids as substrate (85). This may be
due to cardiac growth without sufficient angiogenesis, result-
ing in a hypoxic state; data suggests that a mildly hypoxic
state results in increased glucose utilization (86), and expo-
sure of the developing heart to the oxygen-rich postnatal
environment at birth correlates with a shift from glycolysis as
the major source of ATP production to fatty acid and lactate
oxidation (87). All of these findings support the notion that
disease progression in the heart is correlated with a shift in
energy substrate utilization, with an initially increased de-
pendence on fatty acids and later an increased dependence
on glucose. The R278C hearts show increased levels of mi-
tochondrial 3-ketoacyl-CoA thiolase (involved in fatty acid
synthesis) and acyl-coenzyme A thioesterase 13 and enoyl-
CoA delta isomerase 1 (involved in fatty acid metabolism)
relative to WT hearts (supplemental Table S7). Metabolomic
analysis showed increased levels of eight fatty acids in R278C
hearts relative to WT hearts, compared with only one in-
creased in I79N hearts compared with WT hearts (Table II).
Although it is possible that elevated levels of fatty acids may
be due to decreased fatty acid usage, the increase in protein
levels of enzymes involved in fatty acid metabolism suggest
that the R278C hearts utilize increased levels of fatty acids.
Hence, the 3 month old R278C hearts are likely in a compen-
satory mode while the I79N hearts show a shift to glucose
utilization, suggesting that these hearts have already started
to decompensate and that cardiac growth is not needed for a
switch in metabolism, because these mice do not have car-
diac growth. I79N hearts also show higher levels of creatinine,
a breakdown product of phosphocreatine, relative to WT
hearts, supporting the notion that phosphocreatine is used at
an accelerated rate to meet the energy demands of I79N
hearts.
Proteins Involved in Cellular Defense—Mass spectrometry
also showed that levels of several antioxidants were in-
creased in I79N hearts relative to R278C hearts, including
glutathione, glutathione peroxidase, TRX-1, superoxide dis-
mutase, and the glutathione S-transferases GSTM1, GSTM2,
and GSTM7 (supplemental Table S5). Some of these findings
were verified by Western blot; TRX-1 expression levels were
higher in I79N hearts compared with R278C hearts. GSTM1
showed a trend toward increased levels relative to WT (p 
0.075), whereas glutathione amount was shown to be higher
in metabolomic investigations (Table II). An assay to measure
the antioxidant capacity revealed that antioxidant capacity is
increased in I79N hearts relative to WT hearts, consistent with
increased expression of antioxidants. Thus, it appears that
I79N hearts are subject to more stress, as shown by increased
ubiquitinated and oxidized protein levels. Expression of pro-
teasome subunits and antioxidants may be up-regulated to
cope with this stress.
Proteins Involved with Ca2 Handling—Because previous
reports have shown that increased Ca2 sensitivity in I79N
hearts results in increased intracellular Ca2 levels, it is pos-
sible that these changes in Ca2 levels would directly affect
Ca2-binding proteins. Although several proteins involved in
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calcium handling were up-regulated in I79N hearts compared
with R278C, no Ca2 binding or Ca2 handling protein was
altered in either I79N or R278C hearts when compared with
WT hearts suggesting that altered protein expression levels of
Ca2 binding and handling proteins were not affected by the
increased intracellular Ca2 levels. This is different from the
TnI G203S hearts, which show elevated levels of Ca2 han-
dling proteins S100A10, S110A11 and annexin A2 (56).
Link Between Different Cellular Pathways—No proteomic or
metabolomic analyses of any TnT-FHC animal model have
been previously performed. The proteomic results suggest
that the two main pathways that differentiate the I79N hearts
from the R278C hearts are metabolic processes (metabolism
and protein degradation by the proteasome), and cellular
processes (such as cellular defense). The increased levels of
oxidized proteins suggest that many enzymes are likely to be
oxidized and have lower enzymatic activity. Increased levels
of oxidized proteins in I79N hearts could result from the
decreased proteasome activity because the proteasome is
involved in degrading oxidized proteins (36). It is also possible
that the increased levels of oxidized proteins in these stressed
hearts are due to increased energy production. Increased ATP
production, as may be required in the I79N transgenic heart,
would likely increase mitochondrial ROS production. A previ-
ous report has shown that increased ROS production from
complex III in the mitochondria is proportional to respiration
rate in adult guinea pig ventricular myocytes (88). Increased
ROS levels could cause an increase in proteasome and anti-
oxidant defense proteins to remove the increased levels of
oxidized proteins and reduce the levels of ROS respectively. If
the proteasome itself or activators of the proteasome are
oxidized, then even with higher levels of proteasome, the
activity of most proteasomes would be compromised result-
ing in lower proteasome activity. Independently the need for
more ATP for contraction in I79N hearts would likely result in
increased levels of enzymes involved in ATP production, as
observed in the proteomic data. However, a trend toward
higher levels of AMP in I79N hearts suggest that ATP levels
may be lower, indicating impairment of the enzymes involved
in ATP production occurs, possibly by oxidation of these
enzymes. The R278C hearts also showed a trend toward
increased levels of AMP suggesting that energy production
may be compromised, though to a lesser extent in these
hearts. R278C hearts also showed some signs of altering ATP
production, as L-lactate dehydrogenase B chain was up-reg-
ulated in both I79N and R278C hearts relative to WT hearts
(Table I). Although the R278C mutation is associated with a
better prognosis, some patients with this mutation do present
with dyspnea at ages above 65 years old (17). Hence R278C
hearts may show more significant changes in energy metab-
olism in older hearts. Several other reports suggest that inef-
ficient energy utilization may be a common and important
molecular pathway associated with HCM caused by sarcom-
eric mutations (73, 75, 76, 89). Our results suggest that
inefficient cellular ATP utilization (energetic alterations) and
protein degradation in TnT-related FHC contributes to the
pathogenesis of the disease.
In the previous report of a TnI G203S FHC model, 17
proteins were found to be up-regulated in the G203S hearts
(56). Two of these proteins, cytochrome c oxidase subunit 6A
and 39S ribosomal protein L12 (both mitochondrial), were
found to be increased in I79N hearts relative to WT hearts. The
ribosomal protein L12 was also found to be up-regulated in
R278C hearts. Important structural proteins  cardiac actin,
desmin and dynein light chain roadblock-type I which were
found to be up-regulated in the TnI G203S hearts were not
up-regulated in I79N or R278C hearts, suggesting that these
proteins may be more important for structural changes asso-
ciated with hypertrophy in the G203S hearts (56). Unlike trans-
genic hearts containing TnT I79N or R278C mutations, hearts
containing TnI G203S showed left ventricular hypertrophy by
age 21 weeks, and cardiomyocytes isolated from these hearts
show cellular hypertrophy (56).
In summary, this is the first study to use proteomic and
metabolomic analysis to investigate mice with TnT-related
cardiomyopathies, as well as the first study to compare
mouse models of mild and severe FHC due to a sarcomeric
gene mutation using proteomics or metabolomics. It was
found that FHC was associated with altered expression of
proteasome subunits and antioxidant enzymes, specifically
higher levels in I79N versus R278C hearts. Proteasome activ-
ity was also decreased, and oxidative stress and ubiquitina-
tion were higher in I79N mice. The data suggest that I79N
hearts are subject to more stress, and likely upregulate ex-
pression of antioxidants and proteasome subunits to cope
with increased stress, but these changes in expression are
insufficient for regaining intracellular homeostasis. It is likely
that impaired metabolism in the cytoplasm and mitochondria
leads to increased mitochondrial ROS production resulting in
increased levels of oxidized proteins. In support of this pos-
sibility, an increased level of oxidized proteins was detected in
I79N hearts using the OxyBlot procedure. Increased levels of
ROS could also directly affect the proteasome, resulting in
lower activity. As such, even with similar or higher levels of
proteasome in I79N hearts compared with WT and R278C
hearts, the overall proteasome activity would be decreased in
I79N hearts. Further experiments will determine if the protea-
some from I79N hearts is oxidatively modified.
In I79N hearts there is also metabolic dysregulation of the
glycolytic pathway which is likely to contribute to the patho-
genesis of the disease. It is interesting to note that these
studies revealed more changes in R278C than I79N mice
relative to WT, suggesting that the changes in I79N mice are
likely more profound in nature, because the I79N mutation is
associated with a more severe phenotype than the R278C
mutation. A possible mechanism for the I79N mutation caus-
ing the observed effects may be due to the mutation triggering
conformational changes in TnT which increase the binding of
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Ca2 to TnC. The resulting increase in Ca2 sensitivity of
myofilament contraction affects intracellular Ca2 homeosta-
sis resulting in inefficient sarcomeric ATP utilization (55, 73,
90). The higher demand for ATP may be inducing stress on the
cellular ATP producing pathways: glycolysis, critic acid cycle,
and oxidative phosphorylation. A byproduct of oxidative
phosphorylation is ROS production (91), and increased ATP
production is likely to result in increased ROS production.
Increased ROS production would result in increased levels of
enzymes that reduce ROS levels as well as increased levels of
oxidized proteins (which are both observed in the I79N hearts)
which would strain the UPS. Because the levels of protea-
some subunits in the I79N mice are not decreased it is pos-
sible that increased ROS levels may be directly oxidizing
proteasome subunits and reducing proteasome activity. It is
also possible that due to the increased levels of oxidized
proteins in I79N hearts some of these oxidized proteins which
interact with the proteasome (for degradation) are non-de-
gradable or only slowly degradable, reducing the availability
of the proteasome to act on other substrates, resulting in
reduced overall proteasome activity. The impaired protea-
some activity may result in altered expression of key signaling
pathways enzymes that contribute to cardiac dysfunction.
Proteasome function is vital for protein homeostasis in the
heart because chronic decreased proteasome activity have
been shown to directly cause cardiac dysfunction (66).
Overall, our findings reveal a new pathway (the ubiquitin-
proteasome system) that was not previously known to be
important in TnT-related cardiomyopathies. Our results also
suggest that increases in structural proteins such as -car-
diac actin and desmin are likely to be associated predomi-
nantly with cell enlargement and that cardiac growth is not
needed for switch from fatty acid to glucose metabolism.
Further investigation of these pathways to determine their
involvement in different FHC models as well as the effects of
rectifying these pathways on diseased heart functions is
needed. It is possible that modulating the proteasome activity
in the heart will reduce the cardiac dysfunction observed
during exercise.
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